Radioimmunoscintigraphy in Patients with Ovarian Cancer

REFERENCES

• Rosenberg SA. Principles of cancer management: biologic therapy. In: De Vita VT Jr, Hellmans S, Rosenberg SA, eds. Cancer. Principles and practice of oncology, 5th ed. Philadel-phia: Lippincott-Raven 1997, pp. 349–74, 1502–39.
   Google Scholar
• Muto MG, Kassis Al. Monoclonal antibodies used in the detection and treatment of epithelial ovarian cancer. Cancer 1995; 76: 2016–27.
   PubMed Web of Science ®Google Scholar
• Yancik R. Ovarian cancer. Age contrasts in incidence, histol-ogy, disease stage at diagnosis and mortality. Cancer 1993; 71: 517–23.
   Google Scholar
• Markman M, Bookman MA. Second-line treatment of ovarian cancer. The Oncologist 2000; 5: 26–35.
   PubMedGoogle Scholar
• Kubik-Huch RA, Dorffier W, von Schulthess GK, et al. Value of (18F)-FDG positron emission tomography, com-puted tomography, and magnetic resonance imaging in diag-nosing primary and recurrent ovarian carcinoma. Eur Radiol 2000; 10: 761–7.
   Google Scholar
• Anderson H, Lindegren S, Back T, Jacobsson L, Leser G, Horvath G. The curative and palliative potential of the monoclonal antibody Mov18 labeled with 211At in nude mice with intraperitoneally growing ovarian cancer xenografts-a long-term study. Acta Oncol 2000; 39: 741–5.
   PubMed Web of Science ®Google Scholar
• Kosmas C, Kalofonos HP, Hird V, Epenetos AA. Mono-clonal antibody targeting of ovarian carcinoma. Oncology 1998; 55: 435–46.
   PubMed Web of Science ®Google Scholar
• Kalofonos HP, Giannakenas C, Kosmas C, et al. Radioim-munoscintigraphy in patients with ovarian cancer. Acta Oncol 1999; 38: 629–34.
   PubMed Web of Science ®Google Scholar
• Rubin SC. Monoclonal antibodies in the management of ovarian cancer. A clinical perspective. Cancer 1993; 71: 1602–12.
   Google Scholar
• Neal CE, Swenson LC, Fanning J, Texter JH. Monoclonal antibodies in ovarian and prostate cancer. Semin Nucl Med 1993; 23: 114–26.
   PubMed Web of Science ®Google Scholar
• Taylor-Papadimitriou J, Stewart L, Burchell J, Beverley P. The polymorphic epithelial mucin as a target for immunother-apy. Ann NY Acad Sci 1993; 690: 69–79.
   PubMed Web of Science ®Google Scholar
• Granowska M, Britton KE, Mather ST et al. Radioim-munoscintigraphy with technetium-99m-labelled monoclonal antibody 5M3 in gynaecological cancer. Eur J Nucl Med 1993; 20: 483–9.
   PubMedGoogle Scholar
• Ahlstrom KR, Hietala SO, Stendahl U, Stigbrand T. Ra-dioimmunodetection of ovarian cancer. Acta Oncol 1993; 32: 729–34.
   PubMed Web of Science ®Google Scholar
• Thor A, Gorstein F, Ohuchi N, Szpak CA, Johnston WW, Schlom J. Tumor-associated glycoprotein (TAG-72) in ovarian carcinomas defined by monoclonal antibody B72.3. J Natl Cancer Inst 1986; 76: 995–1006.
   Google Scholar
• Ryuko K, Schol DJ, Snijdewint FG, et al. Characterization of a new MUC1 monoclonal antibody (VU-2-G7) directed to the glycosylated PDTR sequence of MUCL Tumour Biol 2000; 21: 197–210.
   Google Scholar
• Kearse KP, Smith NL, Semer DA, et al. Monoclonal anti-body D56 detects a tumor-associated sialoglycotope expressed on human serous ovarian carcinomas. Int J Cancer 2000; 88: 866–72.
   PubMed Web of Science ®Google Scholar
• Bodey B, Siegel SE, Kaiser HE. Human cancer detection and immunotherapy with conjugated and non-conjugated mono-clonal antibodies. Anticancer Res 1996; 16: 661–74.
   Google Scholar
• Divgi CR. Status of radiolabeled monoclonal antibodies for diagnosis and therapy of cancer. Oncology 1996; 10: 939–53.
   PubMedGoogle Scholar
• Britton KE, Granowska M. Immunoscintigraphy: importance for researchers and patients. Acta Oncol 1996; 35: 313–77.
   PubMed Web of Science ®Google Scholar
• Reily RM, Sandhu J, Alvarez-Diez TM, Galiinger S, Kirsh J, Stem H. Problems of delivery of monoclonal antibodies. Pharmaceutical and pharmacokinetic solutions. Clin Pharm 1995; 28: 126–42.
   Google Scholar
• Davies Q, Perkins AC, Frier M, Watson S, Lalani E, Symonds EM. The effect of circulating antigen on the biodistribution of the engineered human antibody hCTMO1 in a nude mice model. Eur J Nucl Med 1997; 24: 206–9.
   PubMedGoogle Scholar
• Salmassi A, Mettler L, Wolf H, Mantwill K, Sabzeghabai M, Parwa A. Characterization of a Mab to ovarian cancer and its possible diagnostic application. Eur J Gynaecol Oncol 1999; 20: 289–97.
   PubMed Web of Science ®Google Scholar
• Molthoff CF, Buist MR, Kenemans P, Pinedo HM, Boven E. Experimental and clinical analysis of the characteristics of a chimeric monoclonal antibody, Mov18, reactive with an ovarian cancer-associated antigen. J Nucl Med 1992; 33: 2000–5.
   Google Scholar
• Pincas L, Robins PD, Forstrom LA, Mahoney DW, Mullan BP. Clinical experience with radiolabeled monoclonal antibod-ies in the detection of colorectal and ovarian carcinoma recurrence and review of the literature. Nucl Med Commun 1999; 20: 689–96.
   Google Scholar
• Pectasides D, Pateniotis K, Tzimis L, et al. Immunoscintigra-phy with "II-labeled monoclonal antibodies HMFG2 and HMFG1 F(ab'), versus abdominal CT scan in the detection of residual disease in ovarian cancer patients. hit J Cancer 1988; 3: 83–8.
   Google Scholar
• Bakalakos EA, Burak WE. The radioimmunoguided surgery (RIGS) system as a diagnostic tool. Surg Oncol Clin N Am 1999; 8: 129–44.
   PubMedGoogle Scholar
• Blend MJ, Bhadkamkar VA. Impact of radioimmunoscintigra-phy on the management of colorectal and ovarian cancer patients: a retrospective study. Cancer Invest 1998; 16: 431–41.
   PubMed Web of Science ®Google Scholar
• Method MW, Serafini AN, Averette HE, Rodriguez M, Pe-nalver MA, Sevin BU. The role of radioimmunoscintigraphy and computed tomography scan prior to reassessment laparo-tomy of patients with ovarian carcinoma. A preliminary report. Cancer 1996; 77: 2286–93.
   Google Scholar
• Surwit EA, Childers JM, Krag DN, et al. Clinical assessment of t -CYT-103 immunoscintigraphy in ovarian cancer. Gy-necol Oncol 1993; 48: 285–92.
   PubMed Web of Science ®Google Scholar
• Maguire RT, Pascucci VL, Maroli AN, Gulfo JV. Im-munoscintigraphy in patients with colorectal, ovarian, and prostate cancer. Results with site-specific immunoconjugates. Cancer 1993; 72: 3453–62.
   Google Scholar
• Hempling RE, Piver MS, Baker TR, Bakshi S, Gilani SS. Immunoscintigraphy using 'In Cyt103 prior to second look laparotomy in ovarian cancer. A pilot study. Am J Clin Oncol 1994; 17: 331–4.
   Google Scholar
• Low RN, Carter WD, Saleh F, Sigeti JS. Ovarian cancer: comparison of findings with perfluorocarbon-enhanced MR imaging, In-111-CYT-103 immunoscintigraphy, and CT. Radi-ology 1995; 195: 391–400.
   PubMed Web of Science ®Google Scholar
• Nguyen BD, Regan F. In CYT-103 immunoscintigraphy of isolated splenic metastasis from ovarian carcinoma. Clin Nucl Med 1997; 22: 256–7.
   PubMed Web of Science ®Google Scholar
• Epenetos AA, Britton KE, Mather S, et al. Targeting of iodine-123-labelled tumor-associated monoclonal antibodies to ovarian, breast and gastrointestinal tumors. Lancet 1982; 2: 999–1005.
   PubMed Web of Science ®Google Scholar
• Shepherd JH, Granowska M, Britton KE, et al. Tumor-asso-ciated monoclonal antibodies for the diagnosis and assessment of ovarian cancer. Br J Obstet Gynaecol 1987; 94: 160–7.
   PubMedGoogle Scholar
• Pateisky N, Philipp K, Sevelda P, et al. Radioimmunoscintig-raphy using monoclonal antibodies before second-look surgery in patients suffering from ovarian cancer. Gynecol Obstet Invest 1987; 24: 211–6.
   PubMed Web of Science ®Google Scholar
• Critchley M, Brownless S, Pattern M, et al. Radionuclide imaging of epithelial ovarian tumors with 1231-labeled mono-clonal antibody (H317) specific for placental-type alkaline phosphatase. Clin Radiol 1986; 37: 107–12.
   PubMed Web of Science ®Google Scholar
• Epenetos AA, Snook D, Hooker G, et al. Indium-111 labeled monoclonal antibody to placental alkaline phosphatase in the detection of neoplasms of testis, ovary and cervix. Lancet 1985; 2: 350–3.
   PubMed Web of Science ®Google Scholar
• Riklund KE, Edbom G, Makiya R, et al. Radioim-munoscintigraphy of gynecologic tumors with "'I-labeled anti-PLAP monoclonal antibodies. Acta Radiol 1991; 32: 375–80.
   PubMed Web of Science ®Google Scholar
• Barzen G, Mayr AC, Langer M, et al. Radioimmunoscintigra-phy of ovarian cancer with "'I-labeled 0C-125 antibody fragments. Eur J Med 1989; 15: 42–8.
   Google Scholar
• Papazefkos V, Michalas S, Papantoniou V, et al. Comparative study of RIS with the 131I-0C-125 F(ab'), Mab and CT scan prior to second look operation for ovarian cancer. Eur J Obstet Gynecol Reprod Biol 1990; 37: 271–7.
   PubMed Web of Science ®Google Scholar
• Vuillez JP, Levrot E, Mousseau M, et al. Evaluation of the diagnostic usefulness of Ca125 immunoscintigraphy for ovarian carcinoma follow-up after treatment: contribution of this technique. Bull Cancer 1997; 84: 1033–42.
   PubMed Web of Science ®Google Scholar
• Osmers RG, Rybicki T, Meden H, Kuhn W. Does an im-munoscintigraphy with 0C125 affect the prognosis of ovarian cancer? Eur J Gynaecol Oncol 1997; 18: 177–82.
   PubMed Web of Science ®Google Scholar
• Sakahara H, Hosono M, Kobayashi H, et al. Effect of circulating antigen on immunoscintigraphy of ovarian cancer patients using anti-Ca125 monoclonal antibody. Jpn J Cancer 1996; 87: 655–61.
   PubMedGoogle Scholar
• Chung JK, Kang SB, Lee MC, et al. Clinical immunoscintig-raphy of ovarian carcinoma using iodine-131-labeled 145-9 monoclonal antibody. J Nucl Med 1993; 34: 1651–5.
   PubMed Web of Science ®Google Scholar
• Kobayashi H, Sakahara H, Saga T, et al. A human/mouse chimeric monoclonal antibody against Ca125 for radioim-munoimaging of ovarian cancer. Cancer Immunol Im-munother 1993; 37: 143–9.
   PubMed Web of Science ®Google Scholar
• McQuarrie SA, Riauka T, Baum RP, et al. The effects of circulating antigen on the pharmacokinetics and radioim-munoscintigraphic properties of 'Tc labeled monoclonal antibodies in cancer patients. J Pharm Pharmaceut Sci 1998; 1: 115–25.
   PubMedGoogle Scholar
• Tibben JG, Massuger LF, Claessens RA, et al. Tumor detec-tion and localization using 99"'Tc1abeled OV-TL3 Fab' in patients suspected of ovarian cancer. Nucl Med Commun 1992; 13: 885–93.
   PubMed Web of Science ®Google Scholar
• Massuger LF, Kenemans P, Claessens RA, et al. Im-munoscintigraphy of ovarian cancer with indium-ill-labeled OV-TL3 F(ab'), monoclonal antibody. J Nucl Med 1990; 31: 1802–10.
   PubMed Web of Science ®Google Scholar
• Tibben JG, Thomas CM, Massager LF, et al. Humoral anti-OV-TL3 response after the intravenous administration of radiolabeled Fab' or F(ab'), fragments in ovarian cancer patients. Nucl Med Commun 1995; 16: 853–9.
   PubMed Web of Science ®Google Scholar
• Buijs WCAM, Tibben JG, Boerman OC, et al. Dosimetric analysis of chimeric monoclonal antibody cM0V18 IgG in ovarian carcinoma patients after intraperitoneal and intra-venous administration. Eur J Nucl Med 1998; 25: 1552–61.
   PubMedGoogle Scholar
• Molthoff CF, Buist MR, Kenemans P, Pinedo HM, Boven E. Experimental and clinical analysis of the characteristics of a chimeric monoclonal antibody, Mov18, reactive with an ovarian cancer-associated antigen. J Nucl Med 1992; 33: 2000–5.
   Google Scholar
• Crippa F, Buraggi GL, Di Re E, et al. Radioimmunoscintig-raphy of ovarian cancer with the Mov18 monoclonal anti-body. Eur J Cancer 1991; 27: 724–9.
   PubMed Web of Science ®Google Scholar
• Van Zanten-Przybysz I, Molthoff CF, Roos JC, et al. Ra-dioimmunotherapy with intravenously administered "'I-la-beled chimeric monoclonal antibody Movl 8 in patients with ovarian cancer. J Nucl Med 2000; 41: 1168–76.
   Google Scholar
• Qian H, Feng J, Cui H, et al. Clinical evaluation of radioim-munoimaging with 1311-00C183B2 monoclonal antibody against ovarian carcinoma by intraperitoneal injection. Gy-necol Oncol 1992; 47: 216–22.
   PubMed Web of Science ®Google Scholar
• Meredith RF, Partridge EE, Alvarez RD, et al. Intraperi-toneal radioimmunotherapy of ovarian cancer with lutanium-177-CC49. J Nucl Med 1996; 37: 1491–6.
   PubMed Web of Science ®Google Scholar
• Alexander C, Villena-Heinsen CE, Trampert L, et al. Ra-dioimmunoscintigraphy of ovarian tumors with technetium-99m labeled antibody-170: first clinical experiences. Eur J Nucl Med 1995; 22: 645–51.
   PubMedGoogle Scholar
• Alexander C, Villena-Heinsen CE, Schaefer A, Toth L, Schmidt W, Kirsch CM. Monoclonal antibody Mab-170 for immunoscintigraphic detection of ovarian tumor. Am J Ob-stet Gynecol 1999; 181: 513–7.
   PubMed Web of Science ®Google Scholar
• Lieberman G, Buscombe JR, Hilson AJ, Reid WM, Thakrar D, Maclean AB. Preoperative diagnosis of ovarian carcinoma with a novel monoclonal antibody. Am J Obstet Gynecol 2000; 183: 534–40.
   PubMed Web of Science ®Google Scholar
• Granowska M, Mather ST Jobling T, et al. Radiolabeled stripped mucin, 5M3, monoclonal antibody for im-munoscintigraphy of ovarian tumors. hit J Biol Markers 1990; 5: 89–96.
   PubMedGoogle Scholar
• Jobling TW, Granowska M, Britton KE, et al. Radioim-munoscintigraphy of ovarian tumors using a new monoclonal antibody, 5M3. Gynecol Oncol 1990; 38: 486–92.
   PubMed Web of Science ®Google Scholar
• Ind TE, Granowska M, Britton KE, et al. Peroperative radioimmunodetection of ovarian carcinoma using a hand-held gamma detection probe. Br J Cancer 1994; 70: 1263–6.
   PubMed Web of Science ®Google Scholar
• Jager W, Ackermann S. Resection guided by antibodies (RE-GAS) a reappraisal after 10 years. Int .1- Biol Markers 1998; 13: 221–3.
   PubMed Web of Science ®Google Scholar
• Bell J, Mojzisik C, Hinke G, Derman H, Schlom J, Martin E. Intraoperative radioimmunodetection of ovarian cancer using monoclonal antibody B72.3 and a portable gamma-detecting probe. Obstet Gynecol 1990; 76: 607–11.
   Google Scholar
• McIntosh DG, Colcher D, Seemayer T, Smith ML. The intraoperative detection of ovarian adenocarcinoma using radiolabeled CC49 monoclonal antibody and a hand-held gamma-detecting probe. Cancer Biother Radiopharm 1997; 12: 287–94.
   PubMed Web of Science ®Google Scholar
• Finstad CL, Lloyd KO, Federici MG, et al. Distribution of radiolabeled monoclonal antibody MX35 F(ab'), in tissue samples by storage phosphor screen image analysis: evalua-tion of antibody localization to micrometastatic disease in epithelial ovarian cancer. Clin Cancer Res 1997; 3: 1433–42.
   PubMed Web of Science ®Google Scholar
• Rubin SC, Kostakoglu L, Divgi C, et al. Biodistribution and intraoperative evaluation of radiolabeled monoclonal anti-body MX35 in patients with epithelial ovarian cancer. Gy-necol Oncol 1993; 51: 61–6.
   PubMed Web of Science ®Google Scholar
• Perkins AC, Symonds IM, Pimm MV, Price MR, Wastie ML, Symonds EM. Immunoscintigraphy of ovarian carcinoma using a monoclonal antibody (1111n-NCRC48) defining a polymorphic epithelial mucin (PEM) epitope. Nucl Med Commun 1993; 14: 578–86.
   PubMed Web of Science ®Google Scholar
• Zhu H, Jain RK, Baxter LT. Tumor pretargeting for radioim-munodetection and radioimmunotherapy. J Nucl Med 1998; 39: 65–76.
   Google Scholar
• Kalofonos HP, Rusckowski M, Siebecker DA, et al. Imaging of tumor in patients with "'In -labeled biotin and strep-tavidin-conjugated antibodies: preliminary communication. J Nucl Med 1990; 31: 1791–6.
   PubMed Web of Science ®Google Scholar
• Paganelli G, Magnani P, Zito F, et al. Three-step monoclonal antibody tumor targeting in carcinoembryonic antigen posi-tive patients. Cancer Res 1991; 51: 5960–6.
   PubMed Web of Science ®Google Scholar
• Sakahara H, Saga T. Avidin-biotin system for delivery of diagnostic agents. Adv Drug Deliv Rev 1999; 37: 89–101.
   PubMed Web of Science ®Google Scholar
• Fischman AJ, Badich JW, Strauss HW. A ticket to ride: peptide radiopharmaceuticals. J Nucl Med 1993; 34: 2253–63.
   Google Scholar
• Behr TM, Goldenberg DM, Becker W. Reducing the renal uptake of radiolabeled antibody fragments and peptides for diagnosis and therapy: present status, future prospects and limitations. Eur J Nucl Med 1998; 25: 201–12.
   Google Scholar
• Benevento A, Dominioni L, Carcano G, Dionigi R. Intraop-erative localization of gut endocrine tumors with radiolabeled somatostatin analogs and a gamma-detecting probe. Semin Surg Oncol 1998; 15: 239–44.
   PubMedGoogle Scholar
• Giannakenas C, Kalofonos HP, Apostolopoulos D, et al. Scintigraphic imaging of sarcomatous tumors with (ll 'In-DTPA-phe-D-octreotide. Oncology 2000; 58: 18–24.
   PubMed Web of Science ®Google Scholar
• Okarvi SM. Recent developments in 99"'Tc1abelled peptide-based radiopharmaceuticals: an overview. Nucl Med Com-mun 1999; 20: 1093–112.
   PubMed Web of Science ®Google Scholar
• Hashimoto Y, Tanigawa K, Nakashima M, et al. Construc-tion of the single-chain Fv from 196-14 antibody toward ovarian cancer-associated antigen CA125. Biol Pharm Bull 1999; 22: 1068–72.
   PubMed Web of Science ®Google Scholar